Sign In
Buy IMAB
$4.63
+0 (+0%)
At Close: Apr 14, 2026
I-Mab to Participate at the Piper Sandler Healthcare Conference
07:00am, Thursday, 21'st Nov 2024
The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024 ROCKVILLE, Md. , Nov. 21, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB, the "Company"), a U.S.-based global biotech compa
I-Mab Reports Third Quarter 2024 Results
07:00am, Thursday, 14'th Nov 2024
Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
07:00am, Wednesday, 06'th Nov 2024
ROCKVILLE, Md. , Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapie
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
07:00am, Thursday, 31'st Oct 2024
ROCKVILLE, Md. , Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
07:00am, Wednesday, 30'th Oct 2024
- Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024 ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- I-Mab (NA
I-Mab to Participate at the Truist Securities BioPharma Symposium
07:00am, Monday, 28'th Oct 2024
ROCKVILLE, Md. , Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treat
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade
01:05pm, Wednesday, 09'th Oct 2024
IMab (IMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
04:01pm, Monday, 16'th Sep 2024
Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
07:00am, Tuesday, 10'th Sep 2024
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials - Exposure-Response (E-R) Analysis showed a positive correlatio
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
07:00am, Wednesday, 28'th Aug 2024
Completed divestiture of China operations Uliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody) Clinical collaboration and supply agreement with Bri
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
07:00am, Monday, 26'th Aug 2024
ROCKVILLE, Md. , Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies
I-Mab to Release 1H 2024 Financial Results on August 28, 2024
07:00am, Wednesday, 14'th Aug 2024
Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB
I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)
07:00am, Wednesday, 07'th Aug 2024
Engagement is part of I-Mab's commitment to transition to a U.S.-based biotech PwC to serve as independent registered public accounting firm for FY 2024 ROCKVILLE, Md. , Aug. 7, 2024 /PRNewswire/ --
I-Mab Announces Leadership Transitions
07:30am, Monday, 15'th Jul 2024
ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has app
I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastri
